Neovascular Age-related Macular Degeneration of All Subtypes
Conditions
Keywords
wet AMD, SD-OCT, intravitreal injection, central retinal thickness,
Brief summary
Aflibercept (EYLEA®) induces a rapid reduction in central retinal thickness (CRT) for patients suffering from neovascular age-related-macular degeneration.1 This early dramatic reduction in CRT is already observed through week 4. Therefore it might be not necessary to consistently perform each of the three monthly consecutive intravitreal injections of the so-called loading phase.
Detailed description
The aim of this study is to assess whether the retina of some patients has dried up after the first or second intravitreal injection of Aflibercept (EYLEA®) 2mg and in that event, to determine the proportion of these patients The analysis of the characteristics could help identify a morphotype that would predict whether and when the retina will dry up within the first 3 months of treatment. For some patients having an early drying-up, the third monthly injection might be not necessary 50 naïve patients will be included and will receive a monthly injection over 12 weeks with a biweekly follow-up. Morphological and functional characteristics will be recorded at each visit and will be analyzed. The rate of patients with dry SD-OCT will be assessed. The study includes 7 visits. The visits are scheduled on an every 2-week basis from baseline to Week 12. V1 (baseline), V3 and V5, the patient will be injected with Aflibercept (EYLEA®) 2mg. In the other visits, the visual acuity test, Fundus photography, SD-OCT, and/or Fluorescein Angiography are performed
Interventions
PROCEDUREIntravitreal injection
2 mg intravitreal Aflibercept initiated with one injection every 4 weeks for three consecutive doses (loading dose) The duration of the follow-up is 12 weeks. This means 3 injections per patient should be given over the study period
Sponsors
University Hospital, Bordeaux
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Men and women ≥ 50 years of age * Active primary subfoveal choroidal neovascularization (CNV) lesions secondary to AMD including juxtafoveal lesions that affects the fovea as evidenced by FA in the study eye * Signed Informed Consent * Willing, committed, and able to return for ALL clinic visits and complete all study-related procedures.
Exclusion criteria
* Prior treatment with anti-VEGF therapy in the study eye * Active or suspected ocular or periocular infection. * Active severe intraocular inflammation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Occurence of a Dry SD-OCT 12-week after initiation of a treatment by Aflibercept (EYLEA®) 2mg | 12-week after initiation of a treatment by Aflibercept (EYLEA®) 2mg |
Secondary
| Measure | Time frame |
|---|---|
| Time to get a dry SD-OCT after initiation of a treatment by Aflibercept | Every 2 weeks from treatment initiation (inclusion) to week 12 |
| Evolution of morphological and visual modification under Aflibercept (EYLEA®) | Every 2 weeks from treatment initiation (inclusion) to week 12 |
| Occurence of pigment epithelial detachment | Every 2 weeks from treatment initiation (inclusion) to week 12 |
| Evolution of retinal hemorrhage if any | Every 2 weeks from treatment initiation (inclusion) to week 12 |
| Evolution in the atrophic lesions | Every 2 weeks from treatment initiation (inclusion) to week 12 |
| Occurence the central Retinal Thickness | Every 2 weeks from treatment initiation (inclusion) to week 12 |
Countries
France
Contacts
PRINCIPAL_INVESTIGATORJean-François KOROBELNIK, Professor
University Hospital Bordeaux, France
STUDY_CHAIRGeneviève CHENE, MDPhD
University Hospital Bordeaux, France
Outcome results
None listed